Axonics Gestion

Gestion contrôle des critères 2/4

Le PDG Axonics est Ray Cohen, nommé en Oct2013, a un mandat de 11.08 ans. La rémunération annuelle totale est $ 7.37M, composée du salaire de 10.9% et des bonus 89.1%, y compris les actions et options de la société. détient directement 0.57% des actions de la société, d'une valeur de € 19.62M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 7 ans et 5.6 ans.

Informations clés

Ray Cohen

Directeur général

US$7.4m

Rémunération totale

Pourcentage du salaire du PDG	10.9%
Durée du mandat du directeur général	11.1yrs
Propriété du PDG	0.6%
Durée moyenne d'occupation des postes de direction	7yrs
Durée moyenne du mandat des membres du conseil d'administration	5.6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Ray Cohen a-t-elle évolué par rapport aux bénéfices de Axonics?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$6m
Jun 30 2024	n/a	n/a	-US$2m
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$7m	US$800k	-US$6m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$46m
Dec 31 2022	US$5m	US$750k	-US$60m
Sep 30 2022	n/a	n/a	-US$76m
Jun 30 2022	n/a	n/a	-US$77m
Mar 31 2022	n/a	n/a	-US$80m
Dec 31 2021	US$6m	US$625k	-US$80m
Sep 30 2021	n/a	n/a	-US$76m
Jun 30 2021	n/a	n/a	-US$68m
Mar 31 2021	n/a	n/a	-US$63m
Dec 31 2020	US$1m	US$527k	-US$55m
Sep 30 2020	n/a	n/a	-US$66m
Jun 30 2020	n/a	n/a	-US$82m
Mar 31 2020	n/a	n/a	-US$81m
Dec 31 2019	US$6m	US$500k	-US$80m
Sep 30 2019	n/a	n/a	-US$67m
Jun 30 2019	n/a	n/a	-US$49m
Mar 31 2019	n/a	n/a	-US$39m
Dec 31 2018	US$1m	US$430k	-US$32m
Sep 30 2018	n/a	n/a	-US$28m
Jun 30 2018	n/a	n/a	-US$25m
Mar 31 2018	n/a	n/a	-US$20m
Dec 31 2017	US$605k	US$430k	-US$18m

Rémunération vs marché: La rémunération totale de Ray ($USD 7.37M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.95M ).

Rémunération et revenus: La rémunération de Ray a augmenté alors que l'entreprise n'est pas rentable.

PDG

Ray Cohen (65 yo)

11.1yrs

Titularisation

US$7,369,375

Compensation

Mr. Raymond W. Cohen, also known as Ray, is Independent Director of Kestra Medical Technologies, Inc. from July 2024. Mr. Cohen is Venture Advisor of Andera Partners. He focuses on Life Sciences.He works...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Raymond Cohen	CEO & Director	11.1yrs	US$7.37m	0.57% € 19.6m
Kari Keese	Chief Financial Officer	1.1yrs	US$3.76m	0.079% € 2.7m
Rinda Sama	Chief Operating Officer	6.3yrs	US$3.04m	0.17% € 5.7m
John Woock	Executive VP	6.4yrs	US$3.26m	0.15% € 5.2m
Alfred Ford	Chief Commercial Officer	7yrs	US$2.94m	0.085% € 2.9m
Guangqiang Jiang	Chief Technology Officer	11.1yrs	pas de données	pas de données
Neil Bhalodkar	Vice President of Investor Relations	no data	pas de données	pas de données
Aaron Pettit	General Counsel & Chief Compliance Officer	no data	pas de données	pas de données
Michael Williamson	Senior VP	no data	pas de données	pas de données
Karen Noblett	Chief Medical Officer	7.1yrs	US$651.40k	0.067% € 2.3m
Prabodh Mathur	Chief Product Development Officer	10.5yrs	pas de données	pas de données

7.0yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de 0I3 est chevronnée et expérimentée (7 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Raymond Cohen	CEO & Director	11.1yrs	US$7.37m	0.57% € 19.6m
Michael Carrel	Independent Chairman	5.8yrs	US$250.00k	0.035% € 1.2m
Nancy Snyderman	Independent Director	5.6yrs	US$222.50k	0.039% € 1.3m
David Demski	Independent Director	3.8yrs	US$210.00k	0.019% € 639.4k
Robert McNamara	Independent Director	6yrs	US$227.50k	0.029% € 996.0k
Jane Kiernan	Independent Director	5.6yrs	US$225.00k	0.039% € 1.3m
Esteban Lopez	Independent Director	3.3yrs	US$215.00k	0.013% € 442.2k

5.6yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0I3 sont considérés comme expérimentés (ancienneté moyenne 5.6 ans).

Axonics Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Insufficient new directors

Axonics, Inc. Announces Chief Financial Officer Changes

Independent Director recently sold €127k worth of stock

Chief Medical Officer recently sold €751k worth of stock

Axonics, Inc., Annual General Meeting, May 25, 2022

High number of new directors

Recent updates

BBoston Scientific Corporation (NYSE:BSX) completed the acquisition of Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders.

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings released: EPS: US$0 (vs US$0.08 in 3Q 2023)

Axonics, Inc. Prevails in Patent Infringement Lawsuit with Medtronic

Second quarter 2024 earnings released: EPS: US$0.068 (vs US$0.15 loss in 2Q 2023)

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

Axonics, Inc. Receives Regulatory Approval for Recharge-Free SNM System in Australia

Forecast breakeven date pushed back to 2025

First quarter 2024 earnings released: US$0.38 loss per share (vs US$0.19 loss in 1Q 2023)

Forecast to breakeven in 2024

New minor risk - Shareholder dilution

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Medtronic Files Itc Action Against Axonics to Stop Unauthorized Use of Medtronic Innovations

Full year 2023 earnings released: US$0.12 loss per share (vs US$1.28 loss in FY 2022)

Insufficient new directors

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Third quarter 2023 earnings released: EPS: US$0.08 (vs US$0.34 loss in 3Q 2022)

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2023

New minor risk - Share price stability

Axonics, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Axonics, Inc. Announces Chief Financial Officer Changes

Forecast breakeven date moved forward to 2024

Forecast breakeven date moved forward to 2024

Axonics, Inc. Revises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.47 loss in 2Q 2022)

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.50 loss in 1Q 2022)

Full year 2022 earnings released: US$1.28 loss per share (vs US$1.86 loss in FY 2021)

Forecast to breakeven in 2025

Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Now 22% undervalued after recent price drop

Axonics, Inc. Provides Revenue Guidance for 2023

Forecast to breakeven in 2025

Axonics, Inc. to Report Fiscal Year 2022 Results on Jan 11, 2023

Independent Director recently sold €127k worth of stock

Axonics, Inc. Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.39 loss in 3Q 2021)

Axonics, Inc. Updates Revenue Guidance for the Year 2022

Axonics, Inc. to Report Q3, 2022 Results on Oct 31, 2022

Chief Medical Officer recently sold €751k worth of stock

Axonics Announces First Patient Implants in Canada with New Recharge-Free Sacral Neuromodulation System

Second quarter 2022 earnings released: US$0.47 loss per share (vs US$0.59 loss in 2Q 2021)

Axonics, Inc. Updates Revenue Guidance for the Year of 2022

Axonics, Inc. to Report Q2, 2022 Results on Aug 01, 2022

Axonics, Inc. Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator

First quarter 2022 earnings released: US$0.50 loss per share (vs US$0.57 loss in 1Q 2021)

Axonics, Inc. Updates Revenue Guidance for the Fiscal Year 2022

Axonics, Inc. Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System

Axonics, Inc., Annual General Meeting, May 25, 2022

Axonics, Inc. to Report Q1, 2022 Results on May 05, 2022

High number of new directors

Chief Medical Officer recently sold €700k worth of stock

Axonics® Receives FDA Approval for Recharge-Free Sacral Neuromodulation System

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Axonics, Inc. Provides Revenue Guidance for the Fiscal Year 2022

President & CFO recently sold €788k worth of stock

President & CFO recently sold €788k worth of stock

Axonics, Inc. Provides Earning Guidance for the Fourth Quarter and Fiscal Year of 2021

Third quarter 2021 earnings released: US$0.39 loss per share (vs US$0.24 loss in 3Q 2020)

Axonics, Inc. Provides Additional Update on Inter Partes Review Proceedings

Second quarter 2021 earnings released: US$0.59 loss per share (vs US$0.54 loss in 2Q 2020)

Axonics, Inc. Provides Revenue Guidance for the Fiscal Year 2021

Axonics, Inc. Files PMA Supplement with the FDA for Non-Rechargeable Implantable Sacral Neurostimulator

Axonics Receives FDA Approval Further Expanding MRI Labeling